Skip to main content

Table 1 Sample size scenarios

From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Confidence level

Lower limit of CI

Upper limit of CI

Sample size per arm

Total sample size

95%

80

96%

62

124

90%

80

96%

50

100

80%

80

95%

38

76